0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Editorials |

An Editorial Update: What Level of Blood Pressure Control in Chronic Kidney Disease?

Andrew S. Levey, MD; and Cynthia D. Mulrow, MD, MSc, Deputy Editor
[+] Article and Author Information

From Tufts-New England Medical Center, Boston, MA 02111, and the American College of Physicians, Philadelphia, PA 19106.


Acknowledgment: The authors thank Tom Greene, PhD, for his careful review and helpful comments during preparation of this editorial.

Potential Financial Conflicts of Interest: Dr. Levey was an investigator in the Modification of Diet in Renal Disease Study.

Requests for Single Reprints: Andrew S. Levey, MD, Division of Nephrology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111.

Current Author Addresses: Dr. Levey: Division of Nephrology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111.

Dr. Mulrow: American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106-1572.


Ann Intern Med. 2005;143(1):79-81. doi:10.7326/0003-4819-143-1-200507050-00013
Text Size: A A A

Chronic kidney disease affects about 11% of adults in the United States (1). Hypertension causes about 20% of new cases of kidney failure and complicates 60% to 80% of cases of chronic kidney disease caused by other disorders (2). Irrespective of the cause of chronic kidney disease, hypertension increases the risk for important adverse outcomes, such as progressive loss of kidney function and kidney failure, early development and accelerated progression of cardiovascular disease, and premature death. Angiotensin-converting enzyme (ACE) inhibitors are recommended in chronic kidney disease because in addition to lowering blood pressure, they reduce proteinuria, slow the decline of glomerular filtration rate, and delay the onset of kidney failure (3). However, we do not know the optimal level of blood pressure for slowing the progression of kidney disease. In March 2005, we published follow-up data from the Modification of Diet in Renal Disease (MDRD) Study that showed the long-term benefits of 2 years of a lower-than-usual blood pressure in nondiabetic kidney disease (4). At the same time, the Ramipril Efficacy in Nephropathy 2 (REIN-2) Trial suggested no benefit of lower blood pressure in nondiabetic kidney disease (5). The only other randomized, controlled trial of lower blood pressure in nondiabetic kidney disease was the African-American Study of Kidney Disease and Hypertension (AASK), published in 2002, which also showed no benefit (6). Here's our take on the REIN-2 Trial results and how they compare with the other 2 trials.

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)